Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

Despite the clinical success of the third-generation EGFR inhibitor osimertinib as a first-line treatment of EGFR-mutant non-small cell lung cancer (NSCLC), resistance arises due to the acquisition of EGFR second-site mutations and other mechanisms, which necessitates alternative therapies. Dacomiti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Poels, Kamrine E., Schoenfeld, Adam J., Makhnin, Alex, Tobi, Yosef, Wang, Yuli, Frisco-Cabanos, Heidie, Chakrabarti, Shaon, Shi, Manli, Napoli, Chelsi, McDonald, Thomas O., Tan, Weiwei, Hata, Aaron, Weinrich, Scott L., Yu, Helena A., Michor, Franziska
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8211846/
https://ncbi.nlm.nih.gov/pubmed/34140482
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-021-23912-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados